aglatimagene besadenovec
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03576612 | Feb 2018 → Jun 2023 | malignant glioma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03131037 | May 2017 → Dec 2021 | lung cancer | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01997190 | Oct 2013 → Dec 2015 | breast cancer, lung cancer, mesothelioma, ovarian cancer +1 | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00634231 | Oct 2010 → Dec 2015 | ependymoma, malignant glioma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00638612 | Aug 2008 → May 2013 | pancreatic adenocarcinoma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00751270 | Nov 2005 → Jan 2010 | anaplastic astrocytoma, glioblastoma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01913106 | Jun 2007 → Dec 2018 overdue | prostate cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07332000 | Oct 2025 → Aug 2026 overdue | prostate adenocarcinoma | Candel Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04495153 | Oct 2020 → Dec 2024 overdue | non-small cell lung carcinoma | Candel Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02446093 | Oct 2015 → Dec 2025 overdue | adenocarcinoma | Candel Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00870181 | Jan 2008 → Dec 2011 | glioblastoma | Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT00589875 | Mar 2007 → Dec 2015 | anaplastic astrocytoma, glioblastoma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02202564 | Oct 2006 → Oct 2011 | hepatocellular carcinoma | Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT00300521 | Sep 2000 → Nov 2005 | hepatocellular carcinoma | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07660094 | Jun 2026 → Oct 2031 expected | non-small cell lung carcinoma | Candel Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03313596 | Mar 2013 → Dec 2019 | hepatocellular carcinoma | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT01436968 | Sep 2011 → Aug 2024 overdue | prostate cancer | Candel Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02768363 Comparator | May 2016 → Nov 2024 overdue | prostate cancer | Candel Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aglatimagene besadenovec | “local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir.” PMID 29550074 ↗ Feb 20189“local delivery of an adenoviral vector expressing the HSV-tk gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug” PMID 25795132 ↗ Mar 2015 “local delivery of aglatimagene besadenovec (AdV-tk) followed by anti-herpetic prodrug.” PMID 30883662 ↗ Mar 2019 “CAN-2409 (aglatimagene besadenovec) was previously known as AdV-tk” NCT03131037 ↗ |
| Known as | adenovirus-thymidine kinase enzyme | “ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy” NCT00300521 ↗ |
| Known as | AdV-tk | “This investigational new drug application describes a proposed phase I/II study designed to assess the safety and efficacy of AdV-tk gene therapy in combination with standard...” NCT01913106 ↗12“The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver.” NCT03313596 ↗ “local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir.” PMID 29550074 ↗ Feb 2018 “The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.” NCT00589875 ↗ “local delivery of an adenoviral vector expressing the HSV-tk gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug” PMID 25795132 ↗ Mar 2015 “local delivery of aglatimagene besadenovec (AdV-tk) followed by anti-herpetic prodrug.” PMID 30883662 ↗ Mar 2019 “CAN-2409 (aglatimagene besadenovec) was previously known as AdV-tk” NCT03131037 ↗ |
| Known as | Aglatimagen besadenovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | aglatimagene | “Previous studies with aglatimagene besadenovec (CAN-2409, hereafter referred to as aglatimagene) showed synergy with radiation and immune-mediated cytotoxicity in patients with...” PMID 42225101 ↗ Jun 2026 |
| Known as | CAN-2409 | “A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV...” NCT07660094 ↗3“BACKGROUND: For newly diagnosed glioblastoma (GBM), a combination of upfront surgical immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and...” PMID 40120123 ↗ Oct 2025 |
| Known as | Canatak | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Gliatak | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Oncatak | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Pancatak | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Prostata | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Prostatak | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Known as | Virafir | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544993 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “ADV-TK gene therapy” NCT00300521 ↗ |
| Route | Other | “CAN-2409 was injected into the resection bed after standard tumor surgery” NCT00589875 ↗ |